Vacc 4x

Drug Profile

Vacc 4x

Alternative Names: HIV vaccine Vacc-4x; Kick, Kill and Boost strategy - Bionor Pharma; Vacc-4x

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Bionor Immuno
  • Developer Bionor Pharma; Celgene Corporation; Eurocine; Oslo University Hospital; University of Bergen; University of Oslo
  • Class AIDS vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 15 Sep 2016 Bionor plans a triple combination clinical trial BIONAB for HIV-1 infections
  • 13 Jan 2016 Phase-II clinical trials in HIV-1 infections (Combination therapy) in Denmark (Intradermal) (EudraCT2015-003186-28)
  • 21 Dec 2015 Interim efficacy, adverse events and pharmacodynamics data from the phase I/II REDUC trial in HIV-1 infection released by Bionor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top